Establishment Labs Holdings Inc. announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (?Oaktree?). The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged. The remaining two $25 million tranches are amended as follows: Tranche C of $25 million available before December 31, 2024 and upon FDA approval of Motiva Implants® in the U.S. Tranche D of $25 million available before June 30, 2025 and upon both Tranche C being drawn and trailing twelve-month sales exceeding $195 million.

Interest will accrue on Tranches C and D at a fixed rate of 10.0% per annum.